Bank of New York Mellon’s 9 Meters Biopharma NMTR Stock Holding History

Bank of New York Mellon’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-6,655	Closed	-$29K	–	4579
2022 Q3	$29K	Hold	6,655	–	–	﹤0.01%	4406
2022 Q2	$35K	Sell	6,655 -24,705	-79%	-$233K	﹤0.01%	4424
2022 Q1	$376K	Hold	31,360	–	–	﹤0.01%	3880
2021 Q4	$613K	Buy	31,360 +782	+3%	+$17.5K	﹤0.01%	3664
2021 Q3	$796K	Buy	30,578 +6,501	+27%	+$153K	﹤0.01%	3535
2021 Q2	$530K	Buy	24,077 +21,168	+728%	+$520K	﹤0.01%	3745
2021 Q1	$68K	Buy	+2,909	New	+$89.4K	﹤0.01%	4214
2019 Q4	–	Sell	-735	Closed	-$16K	–	4250
2019 Q3	$16K	Hold	735	–	–	﹤0.01%	4194
2019 Q2	$17K	Sell	735 -2,351	-76%	-$70.5K	﹤0.01%	4193
2019 Q1	$119K	Sell	3,086 -348	-10%	-$15K	﹤0.01%	3975
2018 Q4	$158K	Buy	3,434 +1,433	+72%	+$106K	﹤0.01%	3896
2018 Q3	$274K	Buy	2,001 +55	+3%	+$9.45K	﹤0.01%	3855
2018 Q2	$917K	Buy	+1,946	New	+$716K	﹤0.01%	3288

Other funds holding NMTR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ODFS

O'Donnell Financial Services San Rafael, California $340M AUM 23.31% 1-Year Est. Return

Bank of New York Mellon's NMTR Position: Q4 2022 in Review

Bank of New York Mellon sold out of 9 Meters Biopharma (NMTR) in Q4 2022, closing a stake of 6,655 shares — an estimated $29K sold.

Bank of New York Mellon first reported a position in NMTR in Q2 2018 and held it in 13 quarters. The position peaked at $917K in Q2 2018. 42 funds tracked by Wall St. Rank hold NMTR as of Q4 2022.

Bank of New York Mellon reported no remaining 9 Meters Biopharma position as of Q4 2022 after selling out during the quarter.
Bank of New York Mellon sold 6,655 9 Meters Biopharma shares in Q4 2022, an estimated $29K.
Bank of New York Mellon first reported a position in 9 Meters Biopharma in Q2 2018 and held it in 13 quarters.
Bank of New York Mellon's 9 Meters Biopharma position peaked at $917K in Q2 2018.
42 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2022.

Based on Bank of New York Mellon's 13F filing for Q4 2022, filed 14 Feb 2023.